Glaukos (NYSE:GKOS) CFO Sells $1,600,000.00 in Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 16th. The shares were sold at an average price of $160.00, for a total value of $1,600,000.00. Following the completion of the sale, the chief financial officer directly owned 43,906 shares in the company, valued at $7,024,960. This trade represents a 18.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Glaukos Stock Up 3.4%

GKOS opened at $167.10 on Friday. The business has a 50 day moving average of $137.20 and a 200-day moving average of $124.78. The stock has a market capitalization of $9.81 billion, a price-to-earnings ratio of -51.42 and a beta of 0.75. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $184.00.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The business had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.33%. Glaukos’s revenue was up 49.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. As a group, sell-side analysts anticipate that Glaukos Corporation will post -0.57 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on GKOS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research report on Friday, July 17th. Piper Sandler restated an “overweight” rating and set a $195.00 price target (up from $165.00) on shares of Glaukos in a research note on Thursday. UBS Group began coverage on Glaukos in a research report on Tuesday. They issued a “neutral” rating and a $150.00 price objective for the company. HC Wainwright lifted their price objective on Glaukos from $168.00 to $195.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Wall Street Zen cut Glaukos from a “buy” rating to a “hold” rating in a research report on Saturday, July 18th. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $177.33.

Hedge Funds Weigh In On Glaukos

A number of hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC lifted its holdings in shares of Glaukos by 77.2% during the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock valued at $575,844,000 after acquiring an additional 2,329,608 shares during the period. Wellington Management Group LLP increased its position in shares of Glaukos by 10.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock worth $292,004,000 after purchasing an additional 336,266 shares in the last quarter. Primecap Management Co. CA increased its position in shares of Glaukos by 49.8% during the 4th quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after purchasing an additional 1,123,140 shares in the last quarter. State Street Corp lifted its holdings in Glaukos by 0.9% during the 4th quarter. State Street Corp now owns 2,122,402 shares of the medical instruments supplier’s stock valued at $239,640,000 after purchasing an additional 18,040 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its position in Glaukos by 3.5% in the second quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock valued at $206,503,000 after buying an additional 68,497 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Glaukos reported record second-quarter revenue of $185.6 million, up approximately 50% year over year and well above the roughly $151 million analyst consensus. The company’s quarterly loss narrowed to $0.14 per share from $0.24 a year earlier, beating expectations. Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up
• Positive Sentiment: Growth was led by the iDose TR sustained-release glaucoma treatment and Epioxa, supporting stronger sales momentum and improved gross profit. Management now expects 2026 net sales of $680 million to $700 million, well above the approximately $630 million consensus forecast. iDose TR sales are projected at $275 million to $280 million. Glaukos outlines 2026 net sales outlook
• Positive Sentiment: BTIG Research raised its price target from $164 to $193 and maintained a Buy rating, indicating continued confidence in Glaukos’s commercial growth potential. BTIG raises Glaukos price target
• Neutral Sentiment: UBS initiated coverage with a Neutral rating and a $150 price target, suggesting the strong outlook is partly reflected in the valuation. Glaukos remains unprofitable, with a negative net margin, while operating cash flow was negative during the quarter.
• Negative Sentiment: Insider-trading data showed continued selling, including a $1.6 million CFO transaction conducted under a pre-arranged Rule 10b5-1 plan. While not necessarily a signal of deteriorating fundamentals, the sales may temper investor sentiment after the stock’s substantial run-up.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.